Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + orphenadrine is a fixed-dose combination medication used primarily for the relief of acute musculoskeletal pain and muscle spasms. Paracetamol (also known as acetaminophen) acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system, thereby reducing pain and fever. Orphenadrine is a centrally acting muscle relaxant with anticholinergic properties; it works by blocking muscarinic receptors in the central nervous system to reduce muscle spasms and associated discomfort. The combination is commonly prescribed for conditions such as strains, sprains, tension headaches, and other painful musculoskeletal disorders[1][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Paracetamol + orphenadrine.